Skip to main content
. Author manuscript; available in PMC: 2022 Jul 8.
Published in final edited form as: Ann Rheum Dis. 2022 Apr 12;81(7):1006–1012. doi: 10.1136/annrheumdis-2021-221985

Figure 5. The NLRP3 inflammasome activation and proliferation of Tfh cells in the spleens and lymph nodes were inhibited by MCC950 in MRL/lpr mice.

Figure 5.

(A) At two months of age, MRL/lpr female mice had elevated act. caspase-1+ Tfh cells in their spleen in comparison with its congenic strain MRL/Mpl and B6. (B) Marked increases in act. caspase-1+ Tfh cells in the spleen in 12 and 16 weeks old MRL/lpr. MCC950 given every other day from week 10 to week 16 inhibited these increases. (C) Marked increases in circulating IL-1β in older MRL/lpr. The administration of MCC950 inhibited the increase in IL-1β. (D) MCC950 inhibited the increase in splenic weights. (E) MCC950 prevented the increases of lymph node sizes. (F) MCC950 inhibited the increases in anti-dsDNA Ab. (G) PNA staining revealed that MCC950 dramatically reduced proliferating B cells in the spleen. *p<0.05, **p<0.01 and ***p<0.001.